Dr. Stewart Low has served as Quince Therapeutics’ Head of Discovery since May 2022 and is the primary inventor of the company’s precision drug-targeting technology. He has worked on the development of fracture-targeted drugs for the past decade and holds seven patents related to Quince’s core technology. Dr. Low also has spent time conducting research in the autoimmune division of Endocyte, Inc. and in the device-testing group of Nelson Laboratories. In addition, he worked as a postdoctoral research associate in the chemistry department at Purdue University from 2015 until 2018. Dr. Low received a B.Sc in Microbiology from Brigham Young University and a Ph.D. in Bioengineering from the University of Utah.